Paul Jean Shami
Physician in Salt Lake City, UT
License number
Utah 345232-8905
Issued Date
Oct 8, 1997
Expiration Date
Jan 31, 2018
Category
Physician
Type
Physician/Surgeon CS (Schedule 2-5)
Address
Address
Salt Lake City, UT
Personal information
See more information about Paul Jean Shami at radaris.comName
Address
Phone
9758 Cervantes Cir, Sandy, UT 84092
9758 S Cervantes Cir, Sandy, UT 84092
3254 Walnut Cir, Salt Lake City, UT 84121
Professional information
Associate Professor Of Oncology At University Of Utah
Position:
Professor at Hematology and Hematologic Malignancies, Adjunct Professor at University of Utah, Professor at University ofUtah Medical Center, Chief Medical Officer at JSK Therapeutics Inc, Professor of Hematology at University of Utah, Professor at University of Utah, Professor of Medicine at University of Utah Medical Center
Location:
Greater Salt Lake City Area
Industry:
Hospital & Health Care
Work:
Hematology and Hematologic Malignancies
since Jan 2010
-
Professor
University of Utah
since 2010
-
Adjunct Professor
University ofUtah Medical Center
since Jan 2009
-
Professor
JSK Therapeutics Inc
since Jan 2008
-
Chief Medical Officer
University of Utah
since 1997
-
Professor of Hematology
University of Utah
since Sep 1997
-
Professor
University of Utah Medical Center
since Sep 1997
-
Professor of Medicine
Hematology/Oncology Section, SLC VA Medical Center
Jan 2002 - Jan 2005
-
Member and Clinical Investigator
University of Utah Medical Center
Jan 1998 - Jan 2002
-
Assistant Professor
University of Utah Medical Center
Jan 1997 - Jan 1998
-
Assistant Professor
Hematology/Oncology Section, Durham V.A. Medical Center
Jan 1996 - Jan 1997
-
Clinical Director
Duke University Medical Center
Jan 1996 - Jan 1997
-
Assistant Professor
Durham V.A. Medical Center
Jan 1995 - Jan 1997
-
Special Hematology Laboratory Director
Hematology/Oncology Section, Durham V.A. Medical Center
Jan 1994 - Jan 1997
-
Staff Physician
Duke University Medical Center
Jan 1994 - Jan 1996
-
Associate
Education:
American University of Beirut Faculty of Arts and Sciences
BS, Chemistry
BS, Chemistry
Dr. Paul J Shami - MD (Doctor of Medicine)
Hospitals:
Huntsman Cancer Institute
2000 Circle Of Hope Dr SUITE 2E, Salt Lake City 84112
University of Utah Health Care
50 North Medical Dr, Salt Lake City 84132
Huntsman Cancer Institute
2000 Circle Of Hope Dr SUITE 2E, Salt Lake City 84112
University of Utah Health Care
50 North Medical Dr, Salt Lake City 84132
2000 Circle Of Hope Dr SUITE 2E, Salt Lake City 84112
University of Utah Health Care
50 North Medical Dr, Salt Lake City 84132
Huntsman Cancer Institute
2000 Circle Of Hope Dr SUITE 2E, Salt Lake City 84112
University of Utah Health Care
50 North Medical Dr, Salt Lake City 84132
Education:
Medical Schools
American University of Beirut / Faculty of Medicine
American University of Beirut / Faculty of Medicine
Paul Shami, Salt Lake City UT
Work:
Hematology/Oncology
1950 Circle Of Hope Dr, Salt Lake City, UT 84112 University of Utah Hospitals & Clinics
50 N Medical Dr, Salt Lake City, UT 84132
1950 Circle Of Hope Dr, Salt Lake City, UT 84112 University of Utah Hospitals & Clinics
50 N Medical Dr, Salt Lake City, UT 84132
Novel Gene Rno Upregulated In Leukemia Cells By Nitric Oxide And Dmso
US Patent:
2001002, Oct 11, 2001
Filed:
Mar 6, 2001
Appl. No.:
09/799983
Inventors:
Paul Shami - Salt Lake City UT, US
Charles Parker - Salt Lake City UT, US
Charles Parker - Salt Lake City UT, US
International Classification:
C12Q001/68, G01N033/574, C12P021/02, C12N005/06
US Classification:
435/069100, 435/325000, 435/007230, 435/006000
Abstract:
The present invention relates to a novel human gene which has been shown to induce differentiation of cancer cells. The gene is regulated by NO and is named rno. Three isoforms of rno have been isolated and purified, rno-1 (SEQ ID NO: 1), rno-2 (SEQ ID NO: 3), and rno-3 (SEQ ID NO: 5). The rno isoforms each code for a separate amino acid sequence (SEQ ID NOS: 2, 4, & 5 ). The present invention also provides recombinant vectors comprising nucleic acid molecules that code for the rno gene products. In certain embodiments, these recombinant vectors are plasmids. In certain embodiments, these recombinant vectors are prokaryotic or eukaryotic expression vectors. In certain especially preferred embodiments, the nucleic acid coding for the rno gene products are operably linked to a heterologous promoter. The present invention further provides host cells comprising a nucleic acid that codes for the rno gene products (SEQ ID NOS: 2, 4, & 5). The gene products have been shown to induce AML cell differentiation and apoptosis.
Vivo Use Of Glutathione S-Transferase Activated Nitric Oxide Donors
US Patent:
2005017, Aug 4, 2005
Filed:
Mar 21, 2003
Appl. No.:
10/508744
Inventors:
Paul Shami - Salt Lake City UT, US
International Classification:
A61K031/655, A61K031/506, A61K031/495
US Classification:
514150000, 514255010, 514252140
Abstract:
The present invention provides for a method of simultaneously treating both cancer and the Multidrug Resistance Phenotype via inhibition of cellular thiols, such as Glutathione S-Transferase (GST). This enzyme is overproduced in leukemia and solid tumor cells and is one of the main pathways involved in the Multidrug Resistance phenotype. The treatment provides for the administration of a chemically inert pro-drug, designed to be a specific substrate for the GST enzyme that, once cleaved, liberates the bioactive toxin Nitric Oxide (NO) intracellularly at the site of a malignant growth. NO then acts to inhibit the growth of the malignant cells and to induce cellular differentiation and apoptosis therein, effectively treating an existing cancerous condition. Additionally, once NO is liberated from the pro-drug, the remaining structure acts to inhibit further GST activity, providing a treatment for the Multidrug Resistant phenotype.